These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 12915645

  • 1. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel.
    Cagnacci A, Paoletti AM, Renzi A, Orrù M, Pilloni M, Melis GB, Volpe A.
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3621-5. PubMed ID: 12915645
    [Abstract] [Full Text] [Related]

  • 2. Effects of two different oral contraceptives on homocysteine metabolism in women with polycystic ovary syndrome.
    Cagnacci A, Tirelli A, Renzi A, Paoletti AM, Volpe A.
    Contraception; 2006 Apr; 73(4):348-51. PubMed ID: 16531164
    [Abstract] [Full Text] [Related]

  • 3. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial.
    Cagnacci A, Ferrari S, Tirelli A, Zanin R, Volpe A.
    Contraception; 2009 Feb; 79(2):111-6. PubMed ID: 19135567
    [Abstract] [Full Text] [Related]

  • 4. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS.
    J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
    [Abstract] [Full Text] [Related]

  • 5. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance.
    Lemay A, Dodin S, Turcot L, Déchêne F, Forest JC.
    Hum Reprod; 2006 Jan; 21(1):121-8. PubMed ID: 16199428
    [Abstract] [Full Text] [Related]

  • 6. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS.
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
    [Abstract] [Full Text] [Related]

  • 7. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome.
    Mastorakos G, Koliopoulos C, Deligeoroglou E, Diamanti-Kandarakis E, Creatsas G.
    Fertil Steril; 2006 Feb; 85(2):420-7. PubMed ID: 16595221
    [Abstract] [Full Text] [Related]

  • 8. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
    Teede HJ, Meyer C, Hutchison SK, Zoungas S, McGrath BP, Moran LJ.
    Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
    [Abstract] [Full Text] [Related]

  • 9. Effects of ethinyl estradiol and desogestrel on clinical and metabolic parameters in Indian patients with polycystic ovary syndrome.
    Bhattacharya SM, Ghosh M, Basu R.
    J Obstet Gynaecol Res; 2012 Jan; 38(1):285-90. PubMed ID: 22070369
    [Abstract] [Full Text] [Related]

  • 10. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome.
    Bhattacharya SM, Jha A.
    Fertil Steril; 2012 Oct; 98(4):1053-9. PubMed ID: 22795636
    [Abstract] [Full Text] [Related]

  • 11. Effects of ethinyl estradiol combined with desogestrel and cyproterone acetate on glucose tolerance and insulin response to an oral glucose load: a one-year randomized, prospective, comparative trial.
    Jandrain BJ, Humblet DM, Jaminet CB, Scheen AJ, Gaspard UJ, Lefebvre PJ.
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):378-81. PubMed ID: 2142578
    [Abstract] [Full Text] [Related]

  • 12. Metabolic Effects of a Commonly Used Combined Hormonal Oral Contraceptive in Women With and Without Polycystic Ovary Syndrome.
    Adeniji AA, Essah PA, Nestler JE, Cheang KI.
    J Womens Health (Larchmt); 2016 Jun; 25(6):638-45. PubMed ID: 26871978
    [Abstract] [Full Text] [Related]

  • 13. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome.
    Uras R, Orrù M, Pani F, Marotto MF, Pilloni M, Guerriero S, Etzi R, Zedda P, Sorge R, Lello S, Melis GB, Paoletti AM.
    Contraception; 2010 Aug; 82(2):131-8. PubMed ID: 20654753
    [Abstract] [Full Text] [Related]

  • 14. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
    Kriplani A, Periyasamy AJ, Agarwal N, Kulshrestha V, Kumar A, Ammini AC.
    Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
    [Abstract] [Full Text] [Related]

  • 15. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome.
    Charitidou C, Farmakiotis D, Zournatzi V, Pidonia I, Pegiou T, Karamanis N, Hatzistilianou M, Katsikis I, Panidis D.
    Atherosclerosis; 2008 Feb; 196(2):958-65. PubMed ID: 17418849
    [Abstract] [Full Text] [Related]

  • 16. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
    Leelaphiwat S, Jongwutiwes T, Lertvikool S, Tabcharoen C, Sukprasert M, Rattanasiri S, Weerakiet S.
    J Obstet Gynaecol Res; 2015 Mar; 41(3):402-10. PubMed ID: 25319761
    [Abstract] [Full Text] [Related]

  • 17. [Efficacy and metabolic safety of long-term treatment with ethinyl oestradiol/cyproterone and desogestrel/ethinyl oestradiol tablets in women with polycystic ovary syndrome].
    Zhang J, Su M, Xu L, Yang Z, Yin W, Nie Y, Qiao X, Cheng R, Ma Y.
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jul 30; 38(8):917-922. PubMed ID: 30187872
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Fruzzetti F, Perini D, Lazzarini V, Parrini D, Gambacciani M, Genazzani AR.
    Fertil Steril; 2010 Oct 30; 94(5):1793-8. PubMed ID: 19931080
    [Abstract] [Full Text] [Related]

  • 20. Effect of ethinyl estradiol-cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome.
    Karakurt F, Carlioglu A, Kaygusuz I, Gumus II, Uz B, Akdeniz D.
    Arch Gynecol Obstet; 2014 Jan 30; 289(1):135-40. PubMed ID: 23880889
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.